Clinical significance of PEA3 in human breast cancer.
BACKGROUND
Recently, PEA3 has been reported to suppress HER-2/neu overexpression by promoter activity and thereby inhibit tumorigenesis of breast cancer both in vitro and in vivo.


METHODS
The expression of PEA3 and the clinicopathologic features of 89 patients with breast cancer were investigated. The expression of PEA3 was immunohistochemically detected in 42 (47.2%) of 89 patients.


RESULTS
The correlation between the expression of PEA3 and the clinicopathologic features were nil with regard to lymph node metastasis, hormone receptor, blood vessel invasion, and lymphatic vessel invasion. The disease-free survival rate was shorter for the PEA3-negative groups than for the PEA3-positive ones, but with no statistically significant difference. The overall survival rate after surgical resection in patients who were PEA3-positive vs PEA3-negative was 100% vs 87.2%, respectively, at 3 years and 89.8% vs 72.7%, respectively, at 6 years (P =.0472).


CONCLUSIONS
The expression of PEA3 in breast cancer might therefore be a novel prognostic factor.
Kinoshita
Junko
J
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kitamura
Kaoru
K
Tanaka
Shinji
S
Sugimachi
Keishi
K
Ishida
Mayumi
M
Saeki
Hiroshi
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate; D014157:Transcription Factors / Q000032:analysis*
D014157:Transcription Factors; C065788:transcription factor PEA3